Regeneron gets $10M milestone on Phase III results

Bayer and Regeneron Pharmaceuticals announced positive Phase III results for the first of two studies of VEGF Trap-Eye (aflibercept ophthalmic solution) for patients with macular edema due to central retinal vein occlusion. Regeneron get a $10 million milestone payment from Bayer because the trial met its primary endpoint. Release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.